Menu
US
Shop
Request a Quote
Contact Us
US
Literature - Publication Review

Bone morphogenetic protein 8B - a promising therapeutic avenue for NASH treatment

bone-morphogenetic512

The incidence and prevalence of non-alcoholic fatty liver disease (NAFLD), which is characterized by excessive accumulation of lipids within the liver, is progressively rising due to increasing obesity and metabolic syndrome prevalence. For some individuals, NAFLD can progress to non-alcoholic steatohepatitis (NASH), which can lead to liver cirrhosis and hepatocellular carcinoma (HCC). NASH is poorly understood and therapies to treat the disease are lacking. Michele Vacca, from the University of Cambridge in the UK and colleagues sought to investigate the impact of one member of the TGFß-BMP superfamily, BMP8B, on the progression of NASH. Learn more about their study.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Bone morphogenetic protein 8B - a promising therapeutic avenue for NASH treatment

Download Literature - Publication Review